Biodexa Pharma - BDRX EV/Sales Multiple

Public company logo of Biodexa (BDRX)

Biodexa Pharmaceuticals attracts leading biochemists through long-term R&D funding and stock option programs. The EV/Sales trend, as shaped by GURU.Markets quotes, demonstrates a market valuation where the latest value is recorded as 0.00. A stable image within the biotech environment is reinforced by patents for polymer drug delivery formulas, which create a significant barrier to entry for new players in the brain therapy niche.

Biodexa Pharmaceuticals - BDRX Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

Biodexa Pharmaceuticals - analytical breakdowns and key metrics (BDRX)

- share price and consensus valuation forecast:
Initial company analysis:Biodexa Pharma BDRX
Product sample of Biodexa Pharma

The stability of the issuer's long-term value is determined by the ratio of Enterprise Value (EV) to annual sales, which eliminates the impact of debt load on the fundamental valuation. By analyzing the business valuation dynamics via EV/Sales, an investor can track the scaling efficiency of the Q-Sphera technology and the potential for Biodexa Pharmaceuticals (BDRX) to capture the oncology market.